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Abstract  
Background. TF expression is increased in inflammatory atherosclerotic plaques and has been related to 
their thrombogenicity. Blood-borne TF has been also demonstrated to contribute to thrombogenesis. 
However, few studies have evaluated the association of circulating levels of TF with stroke. We investigated 
the association of baseline circulating levels of TF with stroke events occurred in the European Prospective 
Investigation into Cancer and Nutrition (EPIC)-Italy cohort.  
Methods. Using a nested case-cohort design, a center-stratified random sample of 839 subjects (66% 
women, age range 35 to 71 years) was selected as subcohort and compared with 292 strokes in a mean 
follow-up of 9 years. Blood samples were collected at baseline in citrate, plasma was stored in liquid nitrogen 
and TF was measured by ELISA (IMUBIND, TF ELISA, Instrumentation Laboratory, Milan, Italy). The hazard 
ratios and 95% confidence intervals, adjusted by relevant confounders (covariates of TF) and stratified by 
center, were estimated by a Cox regression model using Prentice method.  
Results. Individuals in the highest compared with the lowest quartile of TF plasma levels had significantly 
increased risk of stroke (P for trend 0.026). The association was independent from several potential 
confounders (P for trend 0.013). No differences were observed between men and women. The increase in 
risk was restricted to ischemic strokes (P for trend 0.0091), whereas high levels of TF were not associated 
with the risk of hemorrhagic stroke (P for trend 0.95).  
Conclusions: Our data provide evidence that elevated levels of circulating TF are potential risk factors for 
ischemic strokes.  
Key words: Stroke, Tissue factor, Coagulation, Biomarkers 
Tissue factor (TF) is an integral membrane glycoprotein that is expressed by activated endothelial cells, 
macrophages and vascular smooth muscle cells in response to various inflammatory stimuli [1,2] . When 
exposed to blood flow TF binds coagulation factor VII and its activated form (VIIa), starting the  coagulation 
process and leading ultimately to thrombin generation, fibrin deposition and thrombus formation [3]. 
Coagulation activation and consequent thrombus formation are key mechanisms in the etiology of ischemic 
arterial disease.  
TF expression is increased in inflammatory atherosclerotic plaques and has been related to their 
thrombogenicity (4-8). TF present in the arterial wall has been considered in the past responsible for the 
initiation of the coagulation cascade and thrombus formation (3,4). According to this paradigm, coagulation is 
initiated after a vessel is damaged and blood with its cellular components, particularly platelets, is exposed to 
vessel-wall TF. More recently, also blood-borne TF, mainly generated by  leukocytes and blood platelets, 
was proven to be inherently thrombogenic and could be  involved in thrombus propagation at the site of 
vascular injury. (9-11) 
Several studies have investigated TF levels in blood of  patients with ischemic vascular disease. Blood-
borne TF may contribute to a procoagulant state in patients with acute cardiac and brain thrombotic events 
(12-13). Prospective studies have shown that high circulating TF levels were predictive of an unfavorable 
outcome in patients with acute coronary syndrome or stroke (14, 15). Data provided by Morange and 
coworkers (16) suggest that circulating TF might be a useful new biomarker to evaluate patients with acute 
coronary syndrome. Specifically, circulating TF was associated with mortality and could  be a marker of the 
extent of coronary atherosclerosis and predict future plaque instability and rupture.  
However, only one study focused the attention on the predictive role of circulating TF levels in the 
population. A report from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk 
study, indeed, evaluating  the   association between serum levels of TF and the risk of future coronary 
events in apparently healthy individuals, could not find any independent association (17). 
By using a candidate gene approach (18), we found that TF gene polymorphisms, associated with TF 
expression from human monocytes stimulated by LPS (19),  were associated with  the risk of ischemic stroke 
at young age, while they did not affect ischemic coronary disease. 
In order to better investigate the role of circulating TF in predicting the risk of stroke in the population, we 
performed a large case-cohort study nested in the EPIC-Italy cohorts (20,21). We measured plasma  levels 
of TF in apparently healthy men and women and assessed the risk of future stroke during a follow-up period 
of 11.9 years. 
 
MATERIALS AND METHODS 
Study population and data collection 
The EPIC-Italy cohort analyzed in this study consists of 34,148 participants recruited prospectively in 1993-
1998 by four out of five EPIC Italy centers (Varese, Turin, Naples (women only) and Ragusa) (20-22). The 
study protocol was approved by the Ethics Committee of each recruiting center. At baseline, all participants 
gave written informed consent. Detailed information was collected on lifestyle habits by a standardized 
questionnaire and on usual diet in the previous year by a food frequency questionnaire (23). Weight, height, 
and blood pressure were measured using standardized procedures. For each participant 0.5 ml aliquots of 6 
ml citrated plasma, 6 ml serum, 1 ml red blood cell, and 2 ml buffy coats were stored in liquid nitrogen at -
196°C.     
Study design 
During a mean follow-up of 11.9 years, 292 cases of stroke (159 thrombotic, 68 hemorrhagic strokes and 65 
for which a clear distinction between thrombotic or hemorrhagic stroke was not available) were identified.  
Using a nested case-cohort design (24), a center-stratified sample of 839 non-cases (281 men, 558 women) 
was randomly selected from the parent cohort, forming a subcohort. Because of the random selection from 
the parent cohort, this subcohort also included 2 persons who had developed stroke. 
Case ascertainment 
The end of follow-up was December 31, 2006 for Varese and Naples; December 31, 2008 for Turin and 
Ragusa. Suspected cerebrovascular disease deaths were identified by using  the International Classification 
of Diseases (ICD, 10th Revision) when ICD 10 codes I60-I69 were reported as an underlying cause of death 
or when codes E10-E14, I10-I15, I46, I49, and I70 were reported as an underlying cause in association with 
I60-I69. Fatal cerebrovascular disease was assigned after verification against hospital discharge and clinical 
records. Persons with suspected cerebrovascular disease were identified on hospital discharge forms by 
ICD9-CM codes 342, 433–434, or 436–438 or by procedure codes for carotid revascularization. Ischemic 
thrombotic stroke was diagnosed when brain infarction was mentioned in the diagnosis and/or confirmed on 
the basis of imaging exams (computed tomography or MRI).  
Blood collection and laboratory procedures 
Laboratory analysis were centralized in a specialized laboratory. Samples were analyzed in random order 
and researchers and laboratory personnel were blinded to case status of the samples.   
Tissue-factor was measured on fresh citrated plasma by enzyme-linked immunosorbent assays (25, 26) 
(Imubind TF kit, American Diagnostica, Stamford, CT). The lower detection limit is ≈10 pg/mL. The assay 
recognizes TF-apo, TF, and TF-factor VII complexes and is designed in such a manner as to prevent any 
interference from other coagulation factors or inhibitors of procoagulant activity. The mean intra-assay 
variation between duplicates was 17%.  
D-dimer was measured on citrated plasma by an automated latex-enhanced immunoassay (HemosIL-IL, 
Milan). High sensitivity C reactive protein (CRP) was measured in plasma, by a latex particle-enhanced 
immunoturbidimetric assay (IL Coagulation Systems on ACL9000). Triglycerides and glucose were 
measured in fasting plasma samples, with enzymatic colorimetric method, using commercial kits (I L, Milan, 
Italy), with an automatic analyzer (IL 350).  
 
Statistical analysis 
Baseline characteristics of the subcohort members were summarized using means with standard deviations 
for continuous variables and frequencies for categorical variables. Tissue factor levels were classified into 
quartiles (based on the distributions in the subcohort) with the lowest quartiles as reference for risk 
evaluation. The association between quartile of tissue factor and environmental or metabolic variables was 
assessed by analysis of variance. To estimate the association between tissue factor quartiles and stroke 
risk, Cox proportional-hazard regression modified according to the Prentice method was used, with age as 
the underlying time scale (27). In the counting processes age was the underlying time variable with “entry 
time” defined as age at baseline and “exit time” as age at stroke event or censoring. Hazard ratios (HR) were 
also calculated analyzing tissue factor levels as continuous variables with an increment of 1 standard 
deviation (SD). All models were stratified by centre. We fitted a minimally adjusted model with age and sex 
as covariates (model 1); a multivariable model, with the additional covariates body mass index (BMI, 
continuous), smoking status (never, former, current), total physical activity (28) (inactive, moderately inactive, 
moderately active, and active; entered in the model as a continuous variable), education (≤8, >8 yrs), 
hypertension (yes, no), diabetes (yes, no) and hyperlipidemia (yes, no) (model 2); and a third model further 
adjusted for triglycerides, Cholesterol, HDL, D-Dimers and C-reactive protein (model 3). Multiplicative 
interaction between tissue factor levels (modelled as a continuous variable) and sex or hypertension or C-
reactive protein was tested with cross-product terms. We ran subgroups analyses for ischemic or 
hemorrhagic strokes. For this latter analysis n=66 cases of stroke for which exact classification in ischemic or 
hemorrhagic type was not available were excluded. 
The data analysis was generated using SAS/STAT software, Version 9.1.3 of the SAS System for 
Windows©2009. SAS Institute Inc. and SAS are registered trademarks of SAS Institute Inc., Cary, NC, USA. 
 
RESULTS 
TF levels in the study population. 
Median levels of  circulating TF were 297 pg/ ml (IQR: 185 to 482)  in the subcohort and 343 pg /ml (IQR:232 
to 498) in cases with stroke.  
  
TF and other risk factors 
Table 1 shows the characteristics of the subcohort according to quartiles of circulating TF levels. Circulating 
TF levels were positively but not statistically significantly  associated with triglycerides. Moreover, subjects in 
the highest quartile of circulating TF levels were more frequently men, smokers and more active. 
 
TF levels and the risk of future CAD 
Table 2 shows hazard ratios and 95% confidence intervals for developing stroke in relation to circulating TF 
levels in the whole population and by type of event. After adjusting for age and sex and stratifying by center 
a substantially higher risk for stroke was observed for increasing levels of circulating TF above  the first 
quartile. It increased from the second quartile (circulating TF >185 pg/ml), remained unchanged for the third 
quartile (circulating TF >297 pg/ml) and increased again for highest circulating TF levels (Table 2). Additional 
adjustment for BMI, smoking habit, total physical activity, education, hypertension, diabetes and 
hyperlipidemia did not modify the results (Table 2, model 2), as well as further adjustment for insulin, 
triglycerides, cholesterol, HDL, D-Dimers and C reactive protein (Table 2, model 3). The risk of stroke 
increased by almost 10% for each increase in 1 standard deviation of circulating TF levels. However, this 
hazard ratio was not statistically significant as actually the hazard ratios did not increase linearly according to 
quartiles. 
Findings were essentially the same in men and women (P for interaction between circulating TF and sex was 
equal to 0.91) or in hypertensive or non hypertensive subjects (P for interaction = 0.48). 
After stratification for thrombotic (n=159) or hemorrhagic strokes (n=68), only the risk of ischemic stroke was 
associated with  circulating TF levels (ORIVvsI qtl = 2.25; 1.20-4.21 95%CI), while the risk  of  hemorrhagic 
strokes was not (ORIVvsI qtl = 1.24; 0.56-2.76 95%CI). 
 
Discussion. 
In this large, prospective study among apparently healthy adult men and women, we observed for the first 
time that high levels of circulating TF are associated with an increased risk of future stroke. The association 
was independent from life style risk factors for stroke, such as smoking habits or physical activity or known 
pathological conditions at risk for stroke such as hypertension, diabetes, dyslipidemia, obesity. Further 
adjustment for biomarkers of lipid or glucose metabolism or coagulation activation and inflammation, did not 
change the observed association. 
The association was similar in men and women and in hypertensive or normotensive subjects. However, it 
was specific for ischemic stroke, where a role of TF in  coagulation activation or atherosclerosis could be 
easily conceived. 
Several studies have focused on the role of TF present in atherosclerotic plaques, showing that TF 
expression is increased in inflammatory atherosclerotic plaques and is  associated with plaque 
destabilization at several arterial sites (4-8, 29). More specifically, increased expression of TF has been 
found in high-grade internal carotid stenosis and has been associated with plaque destabilization (8) . Blood-
borne TF activity but not local TF expression predicted cerebrovascular and peripheral vascular disease 
events at 1 year in elderly patients subjected to carotid endoarterectomy for high-grade carotid stenosis (12). 
We measured circulating levels of TF whose  role in coagulation activity and  thrombus formation is quite  
unclear (30, 31). It should be considered that association is not necessarily equal to causation even in a 
prospective study, and circulating TF could be a by-product (or a marker) of a mechanism linked to the risk of 
stroke. Circulating TF could be released by carotid atherosclerosis plaques into the circulation and then be 
just a marker of the risk of stroke linked to their presence.  The higher plasma levels measured, indeed,  
could reflect an increased shedding from atherosclerotic plaques possibly present in carotid arteries, due to 
the direct contact between turbulent circulating blood and the TF present in the atherosclerotic lesion (32). 
Moreover, also blood-borne TF, mainly generated by  leukocytes and blood platelets, was proven to be inherently 
thrombogenic and could be  involved in thrombus propagation at the site of vascular injury. (9-11). Circulating TF could 
be associated with microparticles originating from several types of cells such as vascular endothelium and smooth 
muscle as well as leukocytes and blood platelets.(33-35). In addition, circulating TF may reflect other 
haemostatic/thrombotic disorders related to the pathophysiology of stroke (36, 37), or other environmental 
risk factors for vascular disease or inflammatory markers (38). The association between TF levels and risk 
factors for vascular disease is controversial (17, 38). We found higher TF levels in men, smokers, and 
subjects with high physical activity; moreover they were slightly associated with increased TG levels, but not 
with other markers of lipid or glucose metabolism nor with inflammation.  However, adjustment for such 
possible confounders did not change the association found.  
Circulating TF levels (39, 40) and TF expression by blood cells (41, 42) could be determined by  genetic 
factors. We previously found that TF gene polymorphisms and haplotypes were associated with the risk of 
ischemic stroke at young age (18). The same genetic variants were found to be associated with either 
circulating levels of TF (40) or TF release form circulating lympho-monocytes (19). Moreover TF gene 
promoter haplotypes were associated with carotid intima-media thickness, a condition predisposing to 
ischemic stroke (43). According to the principle of Mendelian randomization (44), circulating TF should be 
considered more a causal risk factor for stroke rather than a marker of  unrecognized exogenous factors. 
In the same Epicor cohort, we have previously reported  higher levels of PAI-1 in association with the risk of 
ischemic but non of  hemorrhagic stroke (36), similarly  to higher  circulating TF levels observed here, while 
we have described higher D-Dimer levels in association with the risk of both ischemic and hemorrhagic 
stroke (37). Taken together, these data suggest that TF and PAI-1, which contribute to fibrin formation and 
prevention of its dissolution, respectively, may better predict  a thrombotic event; on the other hand  D-Dimer, 
which may derive from  more complex blood/vessel wall interactions, could be a predictor of vascular events 
leading to either hemorrhagic or thrombotic stroke. 
 
Strengths and limitations of this study 
Major strengths of our study are its design as a case-cohort study derived from a prospective study, with a 
relatively large sample size, and use of detailed information on lifestyle, anthropometric and biological 
variables, allowing us to control for their possible confounding effect. In contrast, a limitation of the present 
study is that, as it occurs in the greatest majority of large prospective cohort studies, for each individual 
circulating TF could only be assessed in a single plasma sample; thus indications of long-term variation in its 
levels since baseline are lacking.  Another limitation is that samples were stored after collection at -196°C, 
and assayed several years later, thus the possibility of a variable circulating TF concentrations decay during 
long-term storage cannot be excluded. Lastly, residual confounding by factors not measured or adjusted for, 
may explain the observed link between circulating TF and stroke. 
 
To conclude, the findings of this study indicate that elevated plasma levels of circulating TF are potential risk 
factors for ischemic strokes in men and women. Further studies are warranted to replicate these  results. 
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Table 1. Baseline characteristics of subcohort members according to quartiles of circulating TF 
Characteristic Quartiles of TF P-trend* 
 
TF (range) 
No 
I 
<185 
208 
II 
185-297 
210 
III 
298-482 
211 
IV 
>482 
210 
 
  Median, ng/ml 136 239 387 707  
 Mean±SD  
Age, years 50±8 49 ±8 50±8 50±7 0.24 
Body mass index, kg/m
2
 25.9±3.8 26.3±4.5 26.3±4.3 26.0±3.4 0.50 
Cholesterol, mg/dL 227±47 230±47 230±47 227±49 0.79 
Triglycerides, mg/dL 117±62 132±94 133±73 147±94 0.063 
LDL, mg/dL 140±39 141±40 141±38 139±40 0.75 
HDL, mg/dL 64±16 62±16 63±16 60±15 0.72 
Insulin, IU/mL 8.9±4.4 9.0±3.9 9.2±6.9 10.8±9.9 0.16 
Glucose, mg/dL 93±13 96±18 98±24 97±28 0.25 
C-Reactive Protein, mg/L 1.9±2.9 1.5±2.1 1.5±1.9 1.5±1.8 0.11 
D-Dimers, mg/dL 162±137 146±96 151±105 148±87 0.73 
 N (%)  
Men 22.6% 30.0% 33.2% 48.1% <0.0001 
Total physical activity     0.023 
  Inactive 32.2% 28.1% 32.2% 26.2%  
  Moderately inactive 46.2% 36.2% 40.8% 38.1%  
  Moderately active 13.0% 20.5% 10.0% 20.0%  
  Active 8.7% 15.2% 17.1% 15.7%  
Education     0.47 
  ≤8 yrs 48.1% 52.9% 54.5% 43.8%  
  >8 yrs 51.9% 47.1% 45.5% 56.2%  
Current smoker 25.5% 26.2% 27.5% 26.2% 0.013 
Hypertension 17% 18% 20% 21% 0.22 
Dyslipidemia 19% 24% 21% 26% 0.16 
Diabetes 2% 1% 4% 3% 0.20 
*Age and sex adjusted
Table 2. Hazard ratios (95%CI) for developing stroke in relation to circulating TF levels 
 
 Quartiles of circulating Tissue Factor (pg/ml)  
P-for trend 
(median) 
 
Continuous 
(for every SD increase)  
I 
<185 
II 
185-297 
III 
298-482 
IV 
>482 
All strokes (n=292) 
Events/Sub-cohort 43/208  76/210  92/211 81/210   
HR
1
 -1- 1.88 (1.18-3.00)  1.94 (1.23-3.06)  2.01 (1.25-3.23)  0.026 1.10 (0.95-1.28)  
HR
2
 -1- 1.87 (1.13-3.06)  1.86 (1.16-3.01)  2.08 (1.26-3.41)  0.024 1.10 (0.93-1.28)  
HR
3
 -1- 1.73 (1.02-2.93)  1.78 (1.06-3.00)  1.91 (1.15-3.19)  0.013 1.03 (0.87-1.23)  
Ischemic strokes (n=159) 
Events/Sub-cohort 24/208 36/210 52/211 47/210   
HR
1
 -1- 1.61 (0.89-2.92)  1.85 (1.06-3.25)  2.02 (1.13-3.62)  0.036 1.10 (0.92-1.30)  
HR
2
 -1- 1.61 (0.85-3.04)  1.84 (1.01-3.38)  2.25 (1.20-4.21)  0.020 1.11 (0.92-1.35)  
HR
3
 -1- 1.43 (0.71-2.86)  1.71 (0.87-3.38)  2.13 (1.10-4.12)  0.0091 1.08 (0.87-1.33)  
Hemorrhagic strokes (n=68) 
Events/Sub-cohort 12/208  19/210 21/211  16/210   
HR
1
 -1- 1.75 (0.82-3.72)  1.74 (0.84-3.64)  1.29 (0.58-2.87)  0.84 1.00 (0.76-1.32)  
HR
2
 -1- 1.58 (0.72-3.46)  1.68 (0.80-3.50)  1.24 (0.56-2.76)  0.88 0.99 (0.75-1.32)  
HR
3
 -1- 1.48 (0.64-3.44)  1.67 (0.77-3.62)  1.12 (0.49-2.55)  0.95 1.00 (0.99-1.01)  
1
Adjusted for age and sex; stratified by center. 
2
Adjusted for age, sex, BMI, smoking habit, total physical activity, education, hypertension, diabetes and hyperlipidemia; stratified by center. 
3
As model 3, further adjusted for insulin, total and HDL cholesterol, triglycerides, D-dimer and hs-CRP; stratified by center.  
  
 
